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The therapeutic potential of snake venoms for pain control has been previously demon-
strated. In the present study, the antinociceptive effects of Micrurus lemniscatus venom
(MlV) were investigated in experimental models of pain. The antinociceptive activity of
MIV was evaluated using the writhing, formalin, and tail ﬂick tests. Mice motor perfor-
mance was assessed in the rota rod and open ﬁeld tests. In a screening test for new
antinociceptive substances – the writhing test – oral administration of MlV (19.7–1600 mg/
kg) produced signiﬁcant antinociceptive effect. The venom (1600 mg/kg) also inhibited
both phases of the formalin test, conﬁrming the antinociceptive activity. The administra-
tion of MlV (1600 mg/kg) did not cause motor impairment in the rota rod and open ﬁeld
tests, which excluded possible non-speciﬁc muscle relaxant or sedative effects of the
venom. The MIV (177–1600 mg/kg) also increases the tail ﬂick latency response, indicating
a central antinociceptive effect for the venom. In this test, the MlV-induced antinociceptive
effect was long-lasting and higher than that of morphine, an analgesic considered the gold
standard. In another set of experiments, the mechanisms involved in the venom-induced
antinociception were investigated through the use of pharmacological antagonists. The
MlV (1600 mg/kg) antinociceptive effect was prevented by naloxone (5 mg/kg), a non-
selective opioid receptor antagonist, suggesting that this effect is mediated by activation
of opioid receptors. In addition, the pre-treatment with the m-opioid receptor antagonist
CTOP (1 mg/kg) blocked the venom antinociceptive effect, while the k-opioid receptor
antagonist nor-BNI (0.5 mg/kg) or the d-opioid receptor antagonist naltrindole (3 mg/kg)
only partially reduced the venom-induced antinociception. The present study demon-
strates, for the ﬁrst time, that oral administration of M. lemniscatus venom, at doses that
did not induce any motor performance alteration, produced potent and long-lasting
antinociceptive effect mediated by activation of opioid receptors.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.ia Tecidual e Imuno-
, Fundação Oswaldo
Salvador, BA, Brazil.
lsevier OA license.1. Introduction
Physiological pain serves as a warning mechanism that
indicates imminent tissue damage. Chronic pain lacks such
protective function, since it persists for years without
reﬂecting the severity of a lesion or disease, nor does
chronic pain necessarily respond to treatment of the
underlying disease cause (McGreevy et al., 2011). Chronic
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damaging effect on quality of life, has limited therapeutic
success, which may be due, at least in part, to the small
range of useful drugs (O’Connor, 2009). In addition, the
pain is still poorly managed because most existing anal-
gesics for persistent pain are relatively ineffective, have
a high side effect burden and do not reduce pain in all
treated individuals (Woolf, 2010). Therefore, the develop-
ment of new agents withmore powerful analgesic activities
and with lesser side effects is, at present, of great interest.
Since ancient times, natural products have consistently
been an important source of therapeutic agents. Snake
venoms are composed of a wide variety of proteins and
peptides, which are used mainly to paralyze prey and as
a defense against predators (Kapoor, 2010). Moreover, the
property of selectivity of the molecules present in snake
venoms, to their molecular targets, makes these molecules
useful for the design of novel therapeutic drugs. Several
snake venoms and their toxins have analgesic effects
already demonstrated in humans and antinociceptive
properties in animal models of pain. Hannalgesin, a neuro-
toxin from the venom of Ophiophagus hannah, exhibits
antinociceptive activity without causing any neurological
or muscular deﬁcits (Pu et al., 1995). The antinociceptive
effect of the venomof South American rattle snake, Crotalus
durissus terriﬁcus, has also been investigated. There is
evidence that this effect is due to central mechanisms
(Picolo et al., 1998) and mediated by activation of opioid
receptors (Giorgi et al., 1993). In addition, the contribution
of peripheral mechanisms to that antinociception also has
been demonstrated (Picolo et al., 2000, 2003). Crotoxin, the
principal neurotoxin in Crotalus durissus terriﬁcus venom,
has antinociceptive activity in experimental models of pain
(Zhang et al., 2006), and reduced pain in patients with
advanced cancer (Cura et al., 2002). Crotamine, other
neurotoxin from Crotalus durissus terriﬁcus venom, is re-
ported to produce antinociceptive effect 30-fold higher
than that of morphine without any apparent toxicity
(Mancin et al., 1998). In addition, crotalphine, a novel
peptide isolated from this venom, induces potent anti-
nociceptive effect mediated by activation of opioid recep-
tors (Konno et al., 2008; Gutierrez et al., 2008). The venom
of Naja naja atra, a snake of the Elapidae family, presents
relevant antinociceptive activity attributed to a venom
constituent, the neurotoxin cobrotoxin (Chen and
Robinson, 1990; Grasset, 1952; Yang, 1999). Xiong et al.
(1992) showed that this toxin might be clinically useful as
a substitute for morphine in patients with opioid depen-
dence. Nowadays, cobrotoxin is commercially available for
its analgesic effect.
Coral snakes, the representative snakes of the Elapidae
family in the Americas, include the genera Leptomicrurus,
Micruroides, and Micrurus. The latter is found in regions
ranging from the southern of the United States to the
southern of South America (Da-Silva and Sites, 2001).
Experimental studies suggest the presence of a consider-
able spectrum of biological activities of Micrurus venoms,
such as neurotoxic, myotoxic, hemorrhagic, and edemato-
genic (Cecchini et al., 2005; Francis et al., 1997; Gutiérrez
et al., 1992). In addition, many enzymatic activities have
been detected (Cecchini et al., 2005). However, due to thedifﬁculty in maintenance in captivity and of the minute
quantities of venom obtained from Micrurus sp., the phar-
macological properties of most of their components remain
unknown or poorly understood. The present pharmaco-
logical study was undertaken to investigate the anti-
nociceptive property of the Micrurus lemniscatus venom
(MlV). In addition, the mechanisms of the antinociceptive
effect were evaluated.
2. Materials and methods
2.1. Animals
Experiments were performed on male Swiss Webster
mice (18–22 g) obtained from the Animal Facilities of
Centro de Pesquisas Gonçalo Moniz. Animals were housed
in temperature-controlled rooms (22–25 C), under
a 12:12 h light–dark cycle, with access to water and food ad
libitum until use. All behavioral tests were performed
between 8:00 a.m. and 5:00 p.m., and animals were only
used once. Animal care and handling procedures were in
accordance with the International Association for the Study
of Pain guidelines for the use of animals in pain research
(Zimmermann,1983) and the Institutional Animal Care and
Use Committee FIOCRUZ CPqGM009/2011. Every effort was
made to minimize the number of animals used and any
discomfort.
2.2. Compounds, dilutions and administration
Dry crude snake venom of M. lemniscatus (MlV) was
obtained from the Center for the Study of Animal Venom
(NEVA), Salvador, Brazil, and stored at 20 C. The venom,
diluted in physiological saline at the time of use, was
administered by oral route 1 h before testing. The venom
treatment parameters were based on preliminary data
from our laboratory. Indomethacin, naloxone (non-selec-
tive antagonist of opioid receptors), naltrindole (d-opioid
receptor antagonist), and nor-binaltorphimine (Nor-BNI; k-
opioid receptor antagonist) were purchased from Sigma
Chemical Company (St. Louis, MO, USA). D-Phe-Cys-Tyr-D-
Trp-Orn-Thr-Pen-Thr amide (CTOP; m-opioid receptor
antagonist) was purchased from Tocris Bioscience (Bristol,
UK). Diazepam and morphine were purchased from Cris-
tália (Itapira, São Paulo, Brazil). Indomethacin was dis-
solved in Tris HCl 0.1 M pH 8.0 plus physiological saline.
Remaining drugs were dissolved in physiological saline.
The drugs were administered by oral (p.o.), intraperitoneal
(i.p.) or subcutaneous (s.c.) routes. The concentration was
adjusted so that all doses could be administered in a ﬁxed
volume of 200 mL per animal.
2.3. Nociceptive tests
2.3.1. Writhing test
Acetic acid (0.8% v/v, 10 mL/kg) was injected into the
peritoneal cavities of mice, which were placed in a large
glass cylinder and the intensity of nociceptive behavior was
quantiﬁed by counting the total number of writhes occur-
ring between 0 and 30 min after the stimulus injection
(Collier et al., 1968).
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Mice were placed in an open Plexiglas observation
chamber for 10 min in order for them to adapt to their
surroundings. Mice were gently restrained while the
dorsum of the hind paw was subcutaneously administered
with 20 mL of formalin 2.5% (1:100 dilution of stock
formalin solution, 37% formaldehyde in 0.9% saline).
Following injection, the mice was returned to the obser-
vation chamber. Mice were observed from 0 to 10 min
(early phase) and from 10 to 30 min (late phase). The
nociception score was determined by counting the time
that the animal spent licking or biting the injected limb
during the observation time (Dubuisson and Dennis, 1977).
2.3.3. Tail ﬂick test
The tail ﬂick test in mice was conducted as described
elsewhere (D’Amour and Smith, 1941), with minor modi-
ﬁcations. Before the day of the experiment, each animal
was habituated to the restraint cylinder for 5 consecutive
days (20 min per day). On the experimental day, mice were
placed in the restraint cylinder and the tail tip (2 cm) was
immersed in a water bath at 48 C  0.5 C. The latency for
the tail withdrawal reﬂex was measured. Each trial was
terminated after 10 s to minimize the probability of skin
damage. Tail ﬂick latency was measured before (baseline)
and after treatments.
2.4. Assay of motor function
To evaluate possible non-speciﬁc muscle-relaxant or
sedative effects of M. lemniscatus venom, mice were
submitted to the rota rod test (Kuribara et al., 1977). The
rota rod apparatus (Insight, Ribeirão Preto, Brazil) consisted
of a bar with a diameter of 3 cm, subdivided into ﬁve
compartments. The bar rotated at a constant speed of 6
revolutions per min. The animals were selected 24 h
previously by eliminating those mice that did not remain
on the bar for two consecutive periods of 120 s. Animals
were treated with diazepam (10 mg/kg i.p.), venom
(1600 mg/kg p.o.), or vehicle (200 mL p.o.), and 40 min
afterward, were placed on a rotating rod. The resistance to
falling was measured up to 120 s. The results are expressed
as the average time (s) the animals remained on the rota
rod in each group. To assess the possible effects of M.
lemniscatus venom on locomotor activity, mice were eval-
uated in the open-ﬁeld test (Rodrigues et al., 2002). Mice
were treated with diazepam (10 mg/kg i.p.), venom
(1600 mg/kg p.o.), or vehicle (200 mL p.o.), and 40 min
afterward were placed individually in a wooden box
(40  60  50 cm) with the ﬂoor divided into 12 squares.
The number of squares crossed with the four paws was
measured for a period of 3 min.
2.5. Data analysis
All data are presented as means  standard error of the
mean (S.E.M) of measurements made on six animals in
each group. All data were analyzed using the Prism 5
computer software (GraphPad, San Diego, USA). Compari-
sons across three or more treatments were made using
one-way ANOVA with Tukey’s post hoc test or repeatedmeasures two-way ANOVA with Bonferroni’s post hoc test,
when appropriate. Statistical differences were considered
to be signiﬁcant at p< 0.05. For the dose–response analysis,
the data of tail ﬂick latencies were converted to anti-
nociception index (%), according to the formula:
AI ¼ ðtest latency baseline latencyÞ
cut  off timeð10 sÞ  baseline latency 100
3. Results and discussion
The antinociceptive properties of M. lemniscatus venom
were evaluated initially using the writhing test in mice,
a screening tool for the assessment of antinociceptive
properties of new substances (Collier et al., 1968). Prelim-
inary data from our laboratory showed that the oral
administration ofM. lemniscatus venom presents improved
antinociceptive effect in relation to the intraperitoneal
administration (data not shown). So, in the present study
the oral route was used to further characterization of the
antinociceptive properties of M. lemniscatus venom.
Oral administration of MlV (19.7–1600 mg/kg),1 h before
acetic acid injection, produced a signiﬁcant (p < 0.05)
inhibition of acetic acid-induced abdominal constrictions
in mice (Fig. 1). Indomethacin (10 mg/kg i.p.), a standard
NSAID used as a positive control, 30 min before testing also
produced a signiﬁcant inhibition of the acetic acid-induced
writhing response. The writhing test presents a good
sensitivity, although with poor speciﬁcity. Indeed, this test
works not only for analgesics, but also for several other
substances, including some devoid of antinociceptive
action, e.g., adrenergic blockers, muscle relaxants, and
neuroleptics (Le Bars et al., 2001). Thus, a positive result
with this test does not necessarily mean the presence of
antinociceptive activity. To avoid misinterpretation of the
results, we conﬁrmed the antinociceptive effect of MlV
using the formalin test, which has two distinct phases that
can possibly indicate different types of pain (Hunskaar and
Hole, 1987). The early and late phases of the formalin test
have clearly different properties, and therefore it is useful
not only to assess antinociceptive substances but also for
the elucidation of the mechanisms of antinociception
(Shibata et al., 1989). The early phase, named nociceptive,
results essentially from the direct stimulation of noci-
ceptors, whereas the late phase, named inﬂammatory,
involves a period of central and peripheral sensitization
during which inﬂammatory phenomena occur (Hunskaar
and Hole, 1987). Injection of formalin in control animals
induced a biphasic ﬂinching response, with the early phase
ranging from 0 to 10 min (Fig. 2A) and the late phase from
10 to 30 min (Fig. 2B) after the injection. Treatment with
MlV (1600 mg/kg) by oral route 1 h before the formalin
administration caused an antinociceptive effect (p < 0.05)
in both the early and late phases of formalin test. The
results obtained with control groups support the anti-
nociceptive effects of M. lemniscatus venom, since the
saline had no activity, and the standard drug morphine
(5 mg/kg s.c.) also inhibited formalin-induced nociception.
Moreover, relaxing or motor deﬁcit effects were discarded,
since administration of M. lemniscatus venom at thera-
peutic doses (1600 mg/kg) did not affect the motor
Fig. 1. Effects of oral administration of M. lemniscatus venom (MlV) on acetic acid-induced writhing in mice. Mice were treated with MlV (2.19–1600 mg/kg) or
saline (200 mL; control group) by oral route 1 h before acetic acid 0.8% (injected at time zero). Indomethacin (Indo; 10 mg/kg i.p.), the reference drug, was
administered 30 min before the acid injection. Data are expressed as means  S.E.M.; n ¼ 6 mice per group. *Signiﬁcantly different from control group (p < 0.05)
as determined by ANOVA followed by Tukey’s test.
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and in the open ﬁeld (Fig. 3B) tests. As expected, the central
nervous system depressant diazepam (10 mg/kg i.p.)
reduced the time of mice on the rota rod (Fig. 3A) and the
number of crossings on the open ﬁeld (Fig. 3B) after 30 min
of treatmentwith this standard drug (p< 0.001). This result
indicates that the effect of the M. lemniscatus venom
observed in the nociceptive models does not result from
alterations in the locomotor activity of the animals,Fig. 2. Effects of oral administration of M. lemniscatus venom (MlV) on
formalin test in mice. Panels A and B show the effects of MlV on the early
and late phases of formalin-induced ﬂinches, respectively. Mice were treated
with MlV (177 and 1600 mg/kg) or saline (200 mL; control group) by oral
route 1 h before formalin (injected at time zero). Morphine (5 mg/kg s.c.),
the reference drug, was administered 40 min before the formalin injection.
Data are expressed as means  S.E.M.; n ¼ 6 mice per group. *Signiﬁcantly
different from control group (p < 0.05) as determined by ANOVA followed
by Tukey’s test.conﬁrming that this venom induces antinociceptive effect.
In line with the present results, it was demonstrated that
neurotoxins from snake venoms present antinociceptive
activity without causing neurological or motor deﬁcits
(Mancin et al., 1998; Pu et al., 1995).
Nonsteroidal anti-inﬂammatory drugs seem to suppress
only the second phase of formalin test. In contrast, centralFig. 3. Effects of M. lemniscatus venom (MlV) on motor function. Bar graphs
representing (A) the run time on the rota rod and (B) the number of square
crossings in the open ﬁeld test, 1 h after the oral administration of MlV
(1600 mg/kg) or saline (200 mL; control group). Diazepam (DZP; 10 mg/kg),
the reference drug, was administered 30 min before testing. Data are re-
ported as means  SEM; n ¼ 6 mice per group. *Signiﬁcantly different from
the control group (p < 0.001) as determined by ANOVA followed by the
Tukey’s test.
Fig. 4. Characterization of the antinociceptive effect of M. lemniscatus venom (MlV) in the tail ﬂick test. The ﬁgure show data of tail ﬂick latencies represented as
antinociception index (IA). For the dose–response analysis, the effects of increasing doses of MlV (59–1600 mg/kg) were tested. To evaluate the time-course of the
antinociceptive effect, thermal nociceptive threshold was evaluated before and up to 24 h following oral administration of MlV or saline (200 mL; control group).
Morphine (5 mg/kg s.c.), the reference drug, was administered 40 min before the tail ﬂick test. Data are expressed as means  S.E.M.; n ¼ 6 mice per group.
*Signiﬁcantly different from control group (p < 0.05); # signiﬁcantly different from morphine-treated mice group (p < 0.05). Two-way ANOVA followed by the
Bonferroni’s test.
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both phases (Hunskaar and Hole, 1987; Malmberg and
Yaksh, 1992). Considering the inhibitory property of MlV
in both the early and late phases of formalin test, it may be
suggested that its antinociceptive activity is due, at least inFig. 5. Effects of the pharmacological blocked of opioid receptors on the antinocice
latencies represented as antinociception index (IA). The thermal nociceptive thresho
(1600 mg/kg) or saline (200 mL; control group). Morphine (5 mg/kg s.c.), the referen
5 mg/kg i.p.), a non-selective opioid receptor antagonist, was administered 15 min
means  S.E.M.; n ¼ 6 mice per group. *Signiﬁcantly different from control group
ysigniﬁcantly different from NLX þ MlV group (p < 0.05). Two-way ANOVA followpart, to central mechanisms. In fact, snake venoms may
induce antinociceptive effects associated with central
actions (Giorgi et al., 1993; Picolo et al., 1998). In an attempt
to investigate this hypothesis, the effects of treatment with
M. lemniscatus venom were assessed in the tail ﬂick test,ptive effect of M. lemniscatus venom (MlV). The ﬁgure shows data of tail ﬂick
ld was evaluated before and up to 24 h following oral administration of MlV
ce drug, was administered 40 min before the tail ﬂick test. Naloxone (NLX;
before the administration of MlV, morphine or saline. Data are expressed as
(p < 0.05); #signiﬁcantly different from NLX þ Morphine group (p < 0.05);
ed by the Bonferroni’s test.
Fig. 6. Effects of selective opioid receptor antagonists on the antinociceptive
effect of M. lemniscatus venom (MlV). The ﬁgure show data of tail ﬂick
latencies represented as antinociception index (IA). Thermal nociceptive
threshold was evaluated before and up to 24 h following oral administration
of MlV (1600 mg/kg) or saline (200 mL; control group). Morphine (5 mg/kg
s.c.), the reference drug, was administered 40 min before the tail ﬂick test.
Panel A shows the effects of m-opioid receptor antagonist (CTOP; 1 mg/kg
i.p.) on the antinociceptive effect of MlV. CTOP was administered 30 min
after the administration of MlV, morphine or saline. Panel B shows the
effects of k-opioid receptor antagonist (nor-BNI; 0.5 mg/kg s.c.) on the
antinociceptive effect of MlV. Nor-BNI was administered 15 min before the
administration of MlV, morphine or saline. Panel C shows the effects of d-
opioid receptor antagonist (naltrindole; 3.0 mg/kg s.c.) on the anti-
nociceptive effect of MlV. Naltrindole was administered 5 min before the
administration of MlV, morphine or saline. Data are expressed as
means  S.E.M.; n ¼ 6 mice per group. *Signiﬁcantly different from control
group (p < 0.05); #signiﬁcantly different from Antagonist þMorphine group
(p < 0.05); ysigniﬁcantly different from Antagonist þ MlV group (p < 0.05).
Two-way ANOVA followed by the Bonferroni’s test.
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2001). The oral administration of the venom (177–
1600 mg/kg) enhanced the reaction time in the tail-ﬂick test
(Fig. 4; p < 0.05), an effect that lasted 5.5 h. The adminis-
tration of morphine (5 mg/kg s.c.), the reference drug,
40 min before testing caused a signiﬁcant increase in the
latency response just 1 h after administration (p < 0.05). In
addition, the antinociception of the MlV-treated group was
signiﬁcantly higher (p < 0.05) relative to the morphine-
treated group. The data presented in Fig. 4 show that the
antinociceptive effect of the venom was long-lasting and
higher than that of morphine, an effect that is hardly
reached by analgesics clinically available. In fact, neuro-
toxins from venoms usually have high pharmacological
potency. For instance, the antinociceptive effect of crot-
amine from Crotalus durissus terriﬁcus venom is 30-fold
higher than that of morphine (Mancin et al., 1998). This
useful property is probably due to the high afﬁnity and
selectivity with which these toxins interfere with neuronal
mechanisms (Beleboni et al., 2004; Mellor and Usherwood,
2004; Wang and Chi, 2004). The thermal model of the tail
ﬂick test is considered to be a spinal reﬂex, but could also
involve higher neural structures (Jensen and Yaksh,1986; Le
Bars et al., 2001). These characteristics of this model are
helpful tools to investigate the site of action of anti-
nociceptive agents. On the other hand, antinociceptive
activity of opioids with restricted access to the central
nervous systemwas demonstrated in the tailﬂick test (Fürst
et al., 2005), indicating that this test is also sensitive to
peripheral acting opioids. In linewith this idea, it is possible
that M. lemniscatus venom exerts its antinociceptive effect
both by central and peripheral mechanisms.
The fact that M. lemniscatus venom produced anti-
nociception in the tail ﬂick test suggests that it blocks the
neural transmission of pain, like opioids do. Based on this
possibility, the effects of the pharmacological blocked of
opioid receptors on the antinociceptive activity of M. lem-
niscatus venom was evaluated. The maximal anti-
nociception produced by MlV (1600 mg/kg) was completely
prevented in mice pre-treated with naloxone (5 mg/kg i.p.;
15 min before), a non-selective opioid receptor antagonist
(Fig. 5). The inhibitory effect of naloxone was maintained
for 2 h, in line with literature data showing the naloxone
half-life (Ngai et al., 1976). The demonstration that
naloxone antagonizes the MlV-induced antinociception
suggests an opioid-like activity for the venom. Similarly,
administration of the m-opioid receptor antagonist CTOP
(1 mg/kg i.p.) 30 min after the MlV administration, blocked
the antinociceptive effect of venom (Fig. 6A). On the other
hand, the pre-treatment with the k-opioid receptor
antagonist nor-BNI (0.5 mg/kg s.c.; 15 min before) partially
inhibited the venom-induced antinociception (Fig. 6B). The
pre-treatment with naltrindole (3.0 mg/kg s.c.; 5 min
before), a d-opioid receptor antagonist, also reduced the
venom-induced antinociception (Fig. 6C). These results
suggest that opioid receptors, particularly m-opioid recep-
tors, play a major role in the antinociceptive mechanisms of
MlV. This idea is reinforced by literature data showing that
opioid receptors are frequently involved in the anti-
nociceptive effects of snake venoms (Chen et al., 2006;
Giorgi et al., 1993; Picolo et al., 2000; Pu et al., 1995).
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In conclusion, the present study has demonstrated, for
the ﬁrst time, that oral administration of M. lemniscatus
venom, at doses that did not induce any apparent toxicity
or motor performance alterations, produced potent anti-
nociceptive effects. The antinociceptive effect due to M.
lemniscatus venom is mediated by the opioid system,
mainly by the m-opioid receptor. However, a more in-depth
evaluation of the mechanisms involved should be
performed.
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